DD297337A5 - Vorrichtung zum verweilen im magen - Google Patents

Vorrichtung zum verweilen im magen Download PDF

Info

Publication number: DD297337A5
Authority: DD; German Democratic Republic
Prior art keywords: stomach; shape; gastric; lingering; memory material
Prior art date: 1989-08-31

Application number

DD90343736A

Other languages

German (de)

English (en)

Inventor

Takashi Sonobe

Shunsuke Watanabe

Masataka Katsuma

Narushi Takamatsu

Yutaka Konno

Hirokazu Takagi

Original Assignee

��@��@��k��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-31

Filing date

1990-08-30

Publication date

1992-01-09

1990-08-30 Application filed by ��@��@��k��Kk�� filed Critical ��@��@��k��Kk��

1992-01-09 Publication of DD297337A5 publication Critical patent/DD297337A5/de

Links

210000002784 stomach Anatomy 0.000 title claims abstract description 120
239000000463 material Substances 0.000 claims abstract description 101
239000012781 shape memory material Substances 0.000 claims abstract description 54
239000000203 mixture Substances 0.000 claims abstract description 44
239000003814 drug Substances 0.000 claims abstract description 37
229940079593 drug Drugs 0.000 claims abstract description 35
238000000465 moulding Methods 0.000 claims abstract description 17
229960002289 nicardipine hydrochloride Drugs 0.000 claims abstract description 8
AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 claims abstract description 8
235000013305 food Nutrition 0.000 claims abstract description 3
238000012377 drug delivery Methods 0.000 claims abstract 2
230000002496 gastric effect Effects 0.000 claims description 36
229920000636 poly(norbornene) polymer Polymers 0.000 claims description 31
239000011248 coating agent Substances 0.000 claims description 20
239000002184 metal Substances 0.000 claims description 16
239000002775 capsule Substances 0.000 claims description 15
238000000576 coating method Methods 0.000 claims description 15
238000001816 cooling Methods 0.000 claims description 13
239000004372 Polyvinyl alcohol Substances 0.000 claims description 12
229920001577 copolymer Polymers 0.000 claims description 12
229920002451 polyvinyl alcohol Polymers 0.000 claims description 12
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
239000003921 oil Substances 0.000 claims description 11
239000000853 adhesive Substances 0.000 claims description 10
230000001070 adhesive effect Effects 0.000 claims description 10
229920002635 polyurethane Polymers 0.000 claims description 9
239000004814 polyurethane Substances 0.000 claims description 9
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
238000002844 melting Methods 0.000 claims description 8
230000008018 melting Effects 0.000 claims description 8
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 6
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 5
210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
238000000748 compression moulding Methods 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
229940102838 methylmethacrylate Drugs 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
229920003023 plastic Polymers 0.000 claims description 3
239000004033 plastic Substances 0.000 claims description 3
238000003825 pressing Methods 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
239000001856 Ethyl cellulose Substances 0.000 claims description 2
210000001124 body fluid Anatomy 0.000 claims description 2
239000010839 body fluid Substances 0.000 claims description 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
229920001249 ethyl cellulose Polymers 0.000 claims description 2
235000019325 ethyl cellulose Nutrition 0.000 claims description 2
230000009477 glass transition Effects 0.000 claims description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
230000033001 locomotion Effects 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
239000012528 membrane Substances 0.000 claims 4
239000000835 fiber Substances 0.000 claims 3
ZAFFWOKULJCCSA-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate;trimethylazanium;chloride Chemical compound [Cl-].C[NH+](C)C.CCOC(=O)C(C)=C ZAFFWOKULJCCSA-UHFFFAOYSA-N 0.000 claims 2
230000005484 gravity Effects 0.000 claims 2
229920002125 Sokalan® Polymers 0.000 claims 1
125000000129 anionic group Chemical group 0.000 claims 1
239000011230 binding agent Substances 0.000 claims 1
229920006237 degradable polymer Polymers 0.000 claims 1
230000003111 delayed effect Effects 0.000 claims 1
229960004667 ethyl cellulose Drugs 0.000 claims 1
210000004051 gastric juice Anatomy 0.000 claims 1
239000010514 hydrogenated cottonseed oil Substances 0.000 claims 1
239000006210 lotion Substances 0.000 claims 1
229940063559 methacrylic acid Drugs 0.000 claims 1
235000019198 oils Nutrition 0.000 claims 1
229920000083 poly(allylamine) Polymers 0.000 claims 1
230000001105 regulatory effect Effects 0.000 claims 1
230000009182 swimming Effects 0.000 claims 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
230000007774 longterm Effects 0.000 abstract description 5
238000002360 preparation method Methods 0.000 description 48
238000012360 testing method Methods 0.000 description 31
230000000052 comparative effect Effects 0.000 description 26
241000282472 Canis lupus familiaris Species 0.000 description 25
238000005452 bending Methods 0.000 description 21
238000000034 method Methods 0.000 description 20
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
238000001746 injection moulding Methods 0.000 description 15
238000000338 in vitro Methods 0.000 description 12
230000036470 plasma concentration Effects 0.000 description 12
238000007906 compression Methods 0.000 description 10
230000006835 compression Effects 0.000 description 10
239000007921 spray Substances 0.000 description 10
239000000243 solution Substances 0.000 description 9
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
229960001783 nicardipine Drugs 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
230000006870 function Effects 0.000 description 7
235000011187 glycerol Nutrition 0.000 description 7
238000005266 casting Methods 0.000 description 6
239000003822 epoxy resin Substances 0.000 description 6
229920000647 polyepoxide Polymers 0.000 description 6
238000009472 formulation Methods 0.000 description 5
229920003112 high viscosity grade hydroxypropyl cellulose Polymers 0.000 description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000000155 melt Substances 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
239000004014 plasticizer Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
-1 and the like) Polymers 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000007598 dipping method Methods 0.000 description 3
239000005038 ethylene vinyl acetate Substances 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
229920003152 Eudragit® RS polymer Polymers 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000001087 glyceryl triacetate Substances 0.000 description 2
235000013773 glyceryl triacetate Nutrition 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000005304 joining Methods 0.000 description 2
229920003145 methacrylic acid copolymer Polymers 0.000 description 2
229940117841 methacrylic acid copolymer Drugs 0.000 description 2
229940026859 nicardipine hydrochloride 60 mg Drugs 0.000 description 2
239000011049 pearl Substances 0.000 description 2
FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920001610 polycaprolactone Polymers 0.000 description 2
239000004632 polycaprolactone Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229960002622 triacetin Drugs 0.000 description 2
SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 1
QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
206010048908 Seasonal allergy Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
241001455273 Tetrapoda Species 0.000 description 1
239000004433 Thermoplastic polyurethane Substances 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
229920006311 Urethane elastomer Polymers 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
229960000985 ambroxol hydrochloride Drugs 0.000 description 1
229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940125710 antiobesity agent Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
229960002529 benzbromarone Drugs 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940091137 cough suppressants and expectorants Drugs 0.000 description 1
229920003020 cross-linked polyethylene Polymers 0.000 description 1
239000004703 cross-linked polyethylene Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000013013 elastic material Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000010828 elution Methods 0.000 description 1
229960002565 eperisone Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
239000004715 ethylene vinyl alcohol Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
229960003630 ketotifen fumarate Drugs 0.000 description 1
YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
229950002475 mesilate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
RNTIBYGPJVJCCJ-UHFFFAOYSA-N n,n-dimethylmethanamine;ethyl 2-methylprop-2-enoate Chemical compound CN(C)C.CCOC(=O)C(C)=C RNTIBYGPJVJCCJ-UHFFFAOYSA-N 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960000293 pirenzepine hydrochloride Drugs 0.000 description 1
201000004338 pollen allergy Diseases 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
239000005060 rubber Substances 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229960003454 tamoxifen citrate Drugs 0.000 description 1
FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
229960000351 terfenadine Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229920002803 thermoplastic polyurethane Polymers 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Compounds Of Unknown Constitution (AREA)
Manufacture Of Alloys Or Alloy Compounds (AREA)
Glass Compositions (AREA)
Seal Device For Vehicle (AREA)
Materials For Medical Uses (AREA)
Dental Preparations (AREA)

DD90343736A 1989-08-31 1990-08-30 Vorrichtung zum verweilen im magen DD297337A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP22524589		1989-08-31

Publications (1)

Publication Number	Publication Date
DD297337A5 true DD297337A5 (de)	1992-01-09

Family

ID=16826278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90343736A DD297337A5 (de)	1989-08-31	1990-08-30	Vorrichtung zum verweilen im magen

Country Status (18)

Country	Link
EP (1)	EP0415671B1 (fr)
JP (1)	JPH03163011A (fr)
KR (1)	KR910004178A (fr)
CN (1)	CN1049787A (fr)
AT (1)	ATE120367T1 (fr)
AU (1)	AU645518B2 (fr)
CA (1)	CA2024450A1 (fr)
DD (1)	DD297337A5 (fr)
DE (1)	DE69018165T2 (fr)
DK (1)	DK0415671T3 (fr)
ES (1)	ES2072987T3 (fr)
FI (1)	FI904253A7 (fr)
IE (1)	IE67450B1 (fr)
MX (1)	MX22149A (fr)
NO (1)	NO903808L (fr)
NZ (1)	NZ235076A (fr)
PT (1)	PT95141A (fr)
RU (1)	RU2070029C1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005059606A1 (de) *	2005-12-12	2007-06-14	Raumedic Ag	Wirkstoff-Applikationsvorrichtung

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4419818C2 (de) *	1994-06-07	1998-10-22	Lohmann Therapie Syst Lts	Wirkstoffträger zur kontrollierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt mit verzögerter Pyloruspassage und Verfahren zur Herstellung desselben
KR100188281B1 (ko) *	1996-04-22	1999-06-01	윤종용	텔레비젼용 스피커 시스템
DE19850309A1 (de) *	1998-10-30	2000-05-04	Lohmann Therapie Syst Lts	Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
RU2196571C2 (ru) *	1998-12-07	2003-01-20	Санкт-Петербургская Государственная Химико-Фармацевтическая Академия	Средство для лечения заболеваний, вызываемых бактериями и простейшими
US8158143B2 (en)	2000-07-14	2012-04-17	Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh	Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US20050202090A1 (en) *	2002-01-03	2005-09-15	Clarke Allan J.	Novel pharmaceutical dosage forms and method for producing same
AU2003254333A1 (en) *	2002-07-10	2004-02-02	Mnemoscience Gmbh	Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
DE10247689A1 (de) *	2002-10-12	2004-04-22	Martin Rahe	Implantat in der Harnblase
CN1750813A (zh) *	2003-02-19	2006-03-22	尼莫科学有限公司	用于胃肠道和泌尿生殖道的自展装置
DE102004023069A1 (de)	2004-05-11	2005-12-08	Bayer Healthcare Ag	Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004031014A1 (de) *	2004-06-26	2006-01-12	Raumedic Ag	Vorrichtung zur gezielten Freistzung von Stoffen in einem Hohlraum
IL166183A0 (en) *	2005-01-06	2006-01-15	Yissum Res Dev Co	Novel diagnostic and imaging techniques of the gi tract
EP2997953B1 (fr) *	2006-01-18	2018-12-26	Intec Pharma Ltd.	Dispositif d'administration par voie orale d'un agent
RU2008142840A (ru) *	2006-03-30	2010-05-10	Джелесис, Инк. (Us)	Сополимер стирола и малеинового ангидрида/кислоты (варианты), изделие на его основе, способ получения сополимера стирола и малеинового ангидрида/кислоты
CN102149369B (zh)	2008-04-18	2016-08-10	因泰克制药有限公司	卡比多巴/左旋多巴胃滞留给药
US9421169B2 (en) *	2009-11-20	2016-08-23	Covidien Lp	Oral dosage forms for delivery of therapeutic agents
CN102319486A (zh) *	2011-06-21	2012-01-18	四川大学	聚焦超声同步控制形状记忆载药聚合物的形状记忆及药物释放的方法
WO2015187746A1 (fr)	2014-06-02	2015-12-10	Teva Pharmaceutical Industries Ltd.	Forme posologique à rétention gastrique expansible
NZ727659A (en)	2014-06-11	2021-12-24	Massachusetts Inst Technology	Residence structures and related methods
US20170266112A1 (en)	2014-06-11	2017-09-21	Massachusetts Institute Of Technology	Residence structures and related methods
DE102014119576A1 (de)	2014-12-23	2016-06-23	Ernst-Moritz-Arndt-Universität Greifswald	Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten
EP3288604B1 (fr) *	2015-05-01	2021-11-17	Massachusetts Institute of Technology	Dispositifs d'induction à mémoire de forme pouvant être déclenchés
US11576859B2 (en)	2015-10-23	2023-02-14	Lyndra Therapeutics, Inc.	Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CA3007165A1 (fr) *	2015-12-02	2017-06-08	Clexio Biosciences Ltd.	Dispositif de preparation de formes pharmaceutiques a retention gastrique
WO2017100367A1 (fr) *	2015-12-08	2017-06-15	Lyndra, Inc.	Configurations géométriques de systèmes à résidence gastrique
CN109310639A (zh) *	2016-05-27	2019-02-05	林德拉有限公司	用于胃驻留系统的材料结构
BR112018077541A2 (pt) *	2016-07-11	2019-04-30	Intec Pharma Ltd.	formulações orais gastrorretentivas e usos das mesmas
JP2019532947A (ja) *	2016-09-30	2019-11-14	リンドラ，インコーポレイティド	アダマンタン系薬物の持続的送達のための胃内滞留システム
EP3320898A1 (fr)	2016-11-11	2018-05-16	ratiopharm GmbH	Forme posologique comprenant une structure de support et méthode de fabrication
CN110035718B (zh) *	2016-12-02	2021-04-06	克雷西奥生物科技有限公司	胃内滞留系统
US11541015B2 (en)	2017-05-17	2023-01-03	Massachusetts Institute Of Technology	Self-righting systems, methods, and related components
US11207272B2 (en)	2017-05-17	2021-12-28	Massachusetts Institute Of Technology	Tissue anchoring articles
CA3066658A1 (fr) *	2017-06-09	2018-12-13	Lyndra, Inc.	Systemes gastriques a demeure avec films modulant le taux de liberation
US11793751B2 (en) *	2017-09-20	2023-10-24	Lyndra Therapeutics, Inc.	Encapsulation of gastric residence systems
TWI837082B (zh) *	2017-11-22	2024-04-01	美商萊恩卓治療公司	用於胃滯留系統之材料架構
WO2019111132A1 (fr)	2017-12-04	2019-06-13	Clexio Biosciences Ltd.	Système de résidence gastrique à action prolongée
AU2019269636A1 (en)	2018-05-17	2020-11-19	Massachusetts Institute Of Technology	Systems for electrical stimulation
JP2021535090A (ja) *	2018-08-15	2021-12-16	リンドラセラピューティクス，インコーポレイティド	治療薬物の腸内送達のためのシステム
WO2020102629A1 (fr) *	2018-11-15	2020-05-22	Massachusetts Institute Of Technology	Dispositifs à demeure à commande thermique
EP3917598B1 (fr)	2019-02-01	2025-10-29	Massachusetts Institute of Technology	Systèmes pour injection de liquide
US11541216B2 (en)	2019-11-21	2023-01-03	Massachusetts Institute Of Technology	Methods for manufacturing tissue interfacing components
EP4238556A4 (fr) *	2020-10-30	2024-09-25	Triastek, Inc.	Forme pharmaceutique à rétention gastrique
HUE067496T2 (hu)	2020-12-08	2024-10-28	Ruminant Biotech Corp Ltd	Az állatoknak szánt anyagok bejuttatására szolgáló eszközök és módszerek fejlesztése
JP7832721B2 (ja) *	2022-06-03	2026-03-18	ジュニオンラブズピーティーイー．リミテッド	経口投与用の胃内滞留装置
CN116898826B (zh) *	2023-07-12	2026-03-20	哈尔滨商业大学	一种胃滞留形状记忆复合膜的制备方法
WO2025042349A1 (fr) *	2023-08-24	2025-02-27	Junion Therapeutics (Xiamen) Co., Ltd.	Article de résidence gastrique destiné à une administration orale
CN121752250A (zh) *	2023-08-24	2026-03-27	厦门君德医药科技有限公司	一种口服胃滞留物
WO2025195482A1 (fr) *	2024-03-22	2025-09-25	厦门君德医药科技有限公司	Appareil de rétention gastrique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4451260A (en) *	1982-03-26	1984-05-29	Minnesota Mining And Manufacturing Company	Sustained release oral medicinal delivery device
NZ200564A (en) *	1982-05-10	1987-03-06	Ahi Operations Ltd	Device for slowly releasing chemicals into body cavities of animals
CA1273872A (fr) *	1985-05-10	1990-09-11	Larry J. Caldwell	Dispositif liberant un medicament qui peut etre retenu dans l'estomac pendant une periode determinee
US4767627A (en) *	1985-05-29	1988-08-30	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
US5002772A (en) *	1988-05-31	1991-03-26	Pfizer Inc.	Gastric retention system for controlled drug release

1990
- 1990-08-23 JP JP2223353A patent/JPH03163011A/ja active Pending
- 1990-08-24 EP EP90309318A patent/EP0415671B1/fr not_active Expired - Lifetime
- 1990-08-24 AT AT90309318T patent/ATE120367T1/de not_active IP Right Cessation
- 1990-08-24 DE DE69018165T patent/DE69018165T2/de not_active Expired - Fee Related
- 1990-08-24 DK DK90309318.5T patent/DK0415671T3/da active
- 1990-08-24 ES ES90309318T patent/ES2072987T3/es not_active Expired - Lifetime
- 1990-08-28 NZ NZ235076A patent/NZ235076A/xx unknown
- 1990-08-29 PT PT95141A patent/PT95141A/pt unknown
- 1990-08-29 MX MX2214990A patent/MX22149A/es unknown
- 1990-08-29 FI FI904253A patent/FI904253A7/fi not_active IP Right Cessation
- 1990-08-30 NO NO90903808A patent/NO903808L/no unknown
- 1990-08-30 RU SU904831116A patent/RU2070029C1/ru active
- 1990-08-30 IE IE315290A patent/IE67450B1/en not_active IP Right Cessation
- 1990-08-30 DD DD90343736A patent/DD297337A5/de not_active IP Right Cessation
- 1990-08-30 AU AU61990/90A patent/AU645518B2/en not_active Ceased
- 1990-08-31 KR KR1019900013602A patent/KR910004178A/ko not_active Ceased
- 1990-08-31 CA CA002024450A patent/CA2024450A1/fr not_active Abandoned
- 1990-08-31 CN CN90107441A patent/CN1049787A/zh active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005059606A1 (de) *	2005-12-12	2007-06-14	Raumedic Ag	Wirkstoff-Applikationsvorrichtung

Also Published As

Publication number	Publication date
DE69018165D1 (de)	1995-05-04
DK0415671T3 (da)	1995-07-24
AU6199090A (en)	1991-03-07
ES2072987T3 (es)	1995-08-01
CN1049787A (zh)	1991-03-13
JPH03163011A (ja)	1991-07-15
EP0415671A2 (fr)	1991-03-06
IE67450B1 (en)	1996-04-03
EP0415671B1 (fr)	1995-03-29
ATE120367T1 (de)	1995-04-15
NO903808L (no)	1991-03-01
PT95141A (pt)	1992-05-29
CA2024450A1 (fr)	1991-03-01
KR910004178A (ko)	1991-03-28
IE903152A1 (en)	1991-03-27
NZ235076A (en)	1993-02-25
FI904253A7 (fi)	1991-03-01
FI904253A0 (fi)	1990-08-29
EP0415671A3 (en)	1991-08-21
RU2070029C1 (ru)	1996-12-10
AU645518B2 (en)	1994-01-20
DE69018165T2 (de)	1995-08-10
MX22149A (es)	1993-10-01
NO903808D0 (no)	1990-08-30

Legal Events

Date	Code	Title	Description
1998-08-13	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD297337A5 (de)	1992-01-09	Vorrichtung zum verweilen im magen
DE69802543T3 (de)	2013-07-04	Verbesserte multipartikel-tablette mit schnellauflösbarkeit
DE69332082T2 (de)	2003-02-06	Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
DE69212710T2 (de)	1996-12-19	Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften
DE69731847T2 (de)	2006-08-03	Nach einer definierten zeitspanne freisetzende dosisformulierungen und verfahren zu deren herstellung
DE69629797T2 (de)	2004-07-15	Matrix zur gesteuerten freisetzung von arzneistoffen
DE69735002T2 (de)	2006-10-26	Osmotisches Verabreichungssystem für lösliche Dosen
DE69432618T2 (de)	2004-02-19	Arzneimittel mit gesteuertem Beginn und gesteuerter Rate der Freisetzung
DE68904596T2 (de)	1993-05-19	Gastrisches zurueckhaltungssystem zur kontrollierten arzneiabgabe.
DE69022876T2 (de)	1996-05-02	Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
DE69009755T2 (de)	1994-10-20	Orale heilmittelform für dauerverabreichung.
DE69315257T2 (de)	1998-05-14	Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen
DE3811114C2 (de)	1996-05-30	Zweischichtige Dosierungsform zur Abgabe eines Wirkstoffs
DE69535445T2 (de)	2008-01-24	Schmelzextrudierte oral verabreichbare Opioidformulierungen
DE69428862T2 (de)	2002-06-20	Linsenförmig pharmazeutische Tablette mit verzögerter Freigabe
DE69017915T2 (de)	1995-07-27	Zubereitung für den magen.
DE3750619T2 (de)	1995-04-20	System zur Abgabe von Arzneistoffen.
DE19940944B4 (de)	2006-10-12	Retardierte, orale, pharmazeutische Darreichungsformen
EP1113787B1 (fr)	2004-03-03	Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production
DE3625458A1 (de)	1987-02-12	Granulaere form mit verzoegerter freisetzung von pharmazeutisch wirksamen substanzen
DE3320583A1 (de)	1984-12-13	Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE69216910T2 (de)	1997-05-22	Diltiazem enthaltende Zusammensetzung
DD298205A5 (de)	1992-02-13	Verfahren zum herstellen von langzeitwirkenden arzneimittelzubereitungen
EP1110544A2 (fr)	2001-06-27	Utilisation d'un film d'enrobage comme enrobage pour le masquage de goût de formes orales
EP0250648B1 (fr)	1991-08-21	Préparation pharmaceutique pour la libération retardée de l'ibuprofène

DD297337A5 - Vorrichtung zum verweilen im magen - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=16826278

Family Applications (1)

Country Status (18)

Cited By (1)

Families Citing this family (48)

Family Cites Families (5)

Cited By (1)

Also Published As

Similar Documents

Legal Events